Atos SE (AEXAY)
| Previous close | 0.4300 |
| Open | 0.4500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4300 - 0.4500 |
| 52-week range | 0.3400 - 3.2800 |
| Volume | |
| Avg. volume | 11,280 |
| Market cap | 241.521M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 12 May 2021 |
| 1y target est | N/A |
- Globe Newswire
Introducing Eviden's new AI computing portfolio - the ultimate solution to unlock AI’s full potential
BullSequana AI 1200H BullSequana AI 1200H BullSequanaAI 1200H (2) BullSequana AI 1200 Eviden Press Release Introducing Eviden's new AI computing portfolio - the ultimate solution to unlock AI’s full potential Paris, France – May 2, 2024 – Eviden, the Atos Group business leading in advanced computing, today announces its new product line “BullSequana AI.” This full end-to-end offering includes five new AI server ranges optimized for AI workloads and is designed to cater to a diverse range of AI n
- GlobeNewswire
Market update - April 29
Non-binding letter of intent received from the French state to acquire 100% of the Advanced Computing, Mission-Critical Systems and Cybersecurity Products activities of Atos SE’s BDS (Big Data & Security) business Indicative enterprise valuation between €700 million and €1 billionDue diligence phase to start shortly in view of the issuance of a confirmatory non-binding offer by early June 2024 Revision of the parameters of the financial restructuring framework presented on April 9, 2024, to refl
- Globe Newswire
Atos reports first quarter 2024 performance
Press Release Atos reports first quarter 2024 performance1 Q1 2024 Revenue €2,479m, down -2.6% organically Eviden down -3.9% organically, reflecting continued softness in Americas and the UKTech Foundations down -1.5% organically, reflecting lower scope of work with certain customers in Americas and Central Europe Order entry of €1.6bn for a book-to-bill of 64%, compared with 73% in prior year Eviden book-to-bill at 83%, compared with 79% in prior year, driven by stronger demand in High-Performa
